SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

MullenArmy is trending as investors debate whether the project is a persistent 'pump and dump' scam or a community-led 'takeover' aimed at mirroring previous parabolic runs. Conversations are heavily polarized, with many users warning of total loss while others cling to hope for a potential recovery driven by low market capitalization.

Circle Internet Group, Inc. is a financial technology company that enables businesses of all sizes to harness the power of digital currencies and public blockchains for payments, commerce and financial applications worldwide. The company was founded by Jeremy J. Allaire and Patrick Sean Neville in August 2013 and is headquartered in New York, NY.

Circle Internet Group Inc. - Ordinary Shares - Class A

Circle

Circle (CRCL) is experiencing high volatility as investors react to a leaked draft of the Clarity Act, which proposes banning passive yield on stablecoin balances. While some market participants fear this move could weaken demand for USDC and pressure revenue, others see it as a long-term regulatory moat that solidifies Circle's position as a compliant leader in the digital payments infrastructure space.

Maul Coin

Maul Coin is trending as the community rallies around its organic growth, active developer engagement, and the anticipation of a parabolic breakout once official charting becomes available. Investors are actively coordinating on social platforms to push the tokens visibility and market cap, positioning it as a long-term project despite the skepticism typically directed at early-stage meme coins.

Hyperliquid is a layer one (L1) blockchain best known for perpetual futures and spot trading. Beyond its flagship DEX trading platform, the ecosystem supports borrowing, lending, real world assets (RWAs), and a full-fledged Ethereum Virtual Machine (EVM), making it a leading force in decentralized finance (defi).   Just as electronic trading dramatically improved markets in the 2000s, Hyperliquid offers an opportunity for a massive technical upgrade of the existing financial system through a transparent, efficient, and resilient blockchain. HYPE is the native token of the Hyperliquid blockchain, with a maximum supply of 1 billion.

Hype

Community interest in $HYPE is surging as traders weigh its role as a high-performance decentralized perpetual exchange against broader market volatility, with many discussing its potential to capture significant institutional flow. Investors are actively debating the token's long-term utility, the impact of ongoing protocol buybacks, and its positioning as a key competitor in the decentralized finance landscape.

First Solar, Inc. is a solar technology company, which engages in the provision of solar modules. It is involved in the design, manufacture, and sale of cadmium tellurid (CdTe) solar modules, which convert sunlight into electricity. The company was founded by Michael J. Ahearn in 1999 and is headquartered in Phoenix, AZ.

First Solar Inc

First Solar is experiencing a significant breakout driven by Alphabet's acquisition of major utility-scale solar developer Intersect Power, a key long-term customer and buyer of its modules. Investors and the community are focused on the stock's role in powering AI data centers and broader grid electrification, viewing this latest news as a validation of its utility-scale manufacturing dominance.

London-based Quant Network is set to revolutionise blockchain technology with the development of their blockchain operating system Overledger. The experienced team are determined to fulfil the original vision of the internet by creating an open trusted network for people, machines, and data to operate securely and safely.  Overledger -the first interoperable blockchain operating system that facilitates internet-scale development of decentralised, multi-chain applications. Overledger has the ability to unlock and distribute value and applications across current and future blockchains. It is an agnostic platform that connects the world's networks to blockchains and ensures you're not limited to any single a vendor or technology. Overledger is the only platform that facilitates the development of internet-scales development of decentralised, multi-chain applications.

Quant

Quant (QNT) is trending as the community debates its long-term utility in global banking infrastructure versus its recent price stagnation. While some investors are accumulating on dips, citing the project's role in institutional projects like the UK's tokenized deposit pilots, others remain frustrated by the asset's lack of explosive price action.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group shares are facing intense volatility and downward pressure as investors digest a substantial revenue miss and a significant decline in earnings, leading to widespread concern over the company's heavy debt burden and high-leverage business model. While some in the community see the current pullback as a potential value opportunity or a short-squeeze setup, others are aggressively betting against the stock, citing management's struggles to navigate fleet costs and broader travel headwinds.

WhiteFiber, Inc. provides AI and HPC infrastructure & cloud and data center solutions. It operates through the following segments: Cloud Services and Colocation Services. The Cloud Services segment offers computing services to support generative AI workstreams. The Colocation Services segment provides customers with physical space, power and cooling within the data center facility. The company was founded on August 15, 2024 and is headquartered in New York, NY.

Whitefiber Inc.

WhiteFiber, Inc.

WhiteFiber, Inc. is surging following the announcement of a massive $865 million, 10-year colocation contract with Nscale, which serves as a major validator for its AI data center infrastructure strategy. The community is actively debating the stock's potential for a short squeeze due to its low float and institutional backing, with many bulls highlighting the deal as a transformative milestone that significantly bolsters the company's long-term revenue pipeline.

cat in a dogs world

MEW is capturing significant investor attention as a leading contender in the 'cat-themed' meme coin sector, with community members actively discussing its potential to rival established dog-themed tokens. Traders are closely tracking exchange listing rumors and technical chart patterns, fueling debates over whether the current price levels represent a long-term accumulation opportunity or a high-risk gamble.

Pump.fun

Pump.fun is generating significant community discourse, fueled by its position as a major memecoin launchpad and ongoing discussions regarding its unique earnings model and market influence. Investors are actively debating the high volume of memecoin activity on the Solana network, with many community members focusing on the platform's ability to drive virality while weighing the associated risks of speculative trading.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Chip Wilson said the board must be refreshed to empower a creative, brand-first experience.</li><li>He has nominated three independent directors to the board.</li><li>Wilson has called for the board to immediately declassify so that all directors are elected annually by shareholders. &nbsp;</li></ul>Lululemon founder Chip Wilson has launched a proxy fight by nominating three independent directors in an effort to remake the company’s board as the athletic-apparel retailer searches for a new chief executive.&nbsp;Wilson has also submitted a non-binding proposal calling for the board to immediately declassify, so that all directors are elected annually by shareholders.The Lululemon founder has nominated three candidates to the company's board, including former On Running co-CEO Marc Maurer, former ESPN Chief Marketing Officer Laura Gentile, and former Activision CEO Eric Hirshberg.He noted that CEO selection must follow a significant board change to ensure shareholders can trust that the right decision is made and that the new leader can succeed.“The recent CEO change announcement was the third total failure of board oversight, with no clear succession plan in place. Shareholders have no faith that this board can select and support the next CEO without input from a board with stronger product experience,” Wilson stated.“The Board must be refreshed so that a creative, brand-first experience is empowered,” he added.<h2 class="st-heading-2">CEO Departure Sparking Reset</h2>Earlier this month, Lululemon said its CEO, Calvin McDonald, will leave the company. The firm named its finance chief, Meghan Frank, and chief commercial officer, André Maestrini, as co-interim CEOs.The reset at retailers is becoming a sector norm as U.S. President Donald Trump’s tariffs have been hurting sales and eating into profits at several top retailers and wholesalers. Firms have also been seeing consumer demand slow as price pressures continue to weigh on consumers' pockets. Firms from Nestle and Walmart to Coty and Coca-Cola have all changed their CEOs this year.Shares in Lululemon have fallen nearly 44% so far in 2025.Get updates to this developing story <a href="https://stocktwits.com/news-articles/markets/equity/lululemon-founder-launches-proxy-fight-to-change-baord/cL75M5PREx2">directly on Stocktwits.</a> &nbsp;

 A Lululemon corporate logo hangs on the front of their store in Brookfield Place on June 21, 2023, in New York City. (Photo by Gary Hershorn/Getty Images)

Lululemon Founder Targets Board Change Ahead Of CEO Search

The proposal seeks to make boardroom revisions before the athletic-apparel company chooses a new CEO. 

Equity

The proposal seeks to make boardroom revisions before the athletic-apparel company chooses a new CEO

<ul class="summary-bullets"><li>Biogen will obtain exclusive worldwide rights to Vanqua’s investigational drug that targets a protein involved in inflammatory responses.</li><li>Vanqua will receive $70 million upfront payments and will be eligible to receive up to $990 million in milestone payments.</li><li>Biogen will lead all future development, manufacturing, and commercialization efforts for the experimental drug.&nbsp; &nbsp;</li></ul>Biogen Inc. (BIIB) on Friday announced a license agreement with Vanqua Bio granting it exclusive worldwide rights to the latter’s preclinical drug candidate targeting a range of inflammatory disorders.Under the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investors.biogen.com/news-releases/news-release-details/biogen-licenses-oral-c5ar1-antagonist-vanqua-bio-expand">deal</a>, Biogen will obtain exclusive worldwide rights to Vanqua’s investigational drug that targets a protein involved in inflammatory responses.<h2 class="st-heading-2">Terms Of The Deal</h2>Vanqua will receive $70 million in upfront payments and be eligible to receive up to $990 million in milestone payments, in addition to tiered royalties on potential net sales, as per the agreement. Biogen will lead all future development, manufacturing, and commercialization efforts of the experimental drug.Jane Grogan, Executive Vice President and Head of Research at Biogen, said that advancing the program will enable it to deepen focus on immunological diseases.Biogen expects to file an application with the U.S. Food and Drug Administration for approval of the candidate in 2027, if results remain supportive. In preclinical studies, the program demonstrated activity as well as a safety and tolerability profile supportive of advancing it into clinical development, the company noted.Last year, Biogen also acquired privately held Human Immunology Biosciences for up to $1.8 billion to expand its immunology portfolio.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2><a href="https://stocktwits.com/symbol/BIIB">BIIB stock</a> rose 1% on Friday morning at the time of writing. On Stocktwits, retail sentiment around BIIB stayed within the ‘bullish’ territory over the past 24 hours, while message volume remained at ‘low’ levels.<figure class="image"><img style="aspect-ratio:620/59;" src="data:image/png;base64,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" width="620" height="59" alt="BIIB's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Oct. 24, 2025 | Source: Stocktwits"><figcaption>BIIB's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Oct. 24, 2025 | Source: Stocktwits</figcaption></figure>According to Koyfin data, 16 of the 35 analysts covering Biogen rate it ‘Buy’ or higher, while 19 rate it ‘Hold’. The stock has an average price target of $172.55, representing a potential upside of about 14%.BIIB stock is down by 1% this year and by about 18% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/eli-lilly-to-acquire-adverum-biotechnologies/cLGJ8N0R3tc">Eli Lilly To Acquire Adverum Biotechnologies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration the logo of Biogen is seen on a smartphone with the FDA logo in the background. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)  

Biogen Licenses Vanqua Bio’s Immunology Drug In $1.06B Deal

Biogen will lead all future development, manufacturing, and commercialization efforts for the experimental drug. 

<ul class="summary-bullets"><li>The Pennsylvania-headquartered company raised its full-year net sales guidance to $3.06 billion to $3.07 billion, up from $3.04 billion to $3.06 billion.&nbsp;</li><li>The company is banking on strong demand for its high-value product (HVP) components used in GLP-1 drugs for weight loss and diabetes management.&nbsp;</li><li>For Q3, West Pharmaceutical reported adjusted and diluted EPS of $1.92, compared to $1.85 in the same period last year.&nbsp; &nbsp;</li></ul>Shares of West Pharmaceutical Services (WST) soared 12% on Thursday afternoon after the company increased its full-year earnings guidance after its third-quarter earnings beat Wall Street expectations.The Pennsylvania-headquartered company, which manufactures packaging components and delivery systems for injectable drugs and healthcare products, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://investor.westpharma.com/news-releases/news-release-details/west-reports-third-quarter-2025-results">raised</a> its full-year net sales guidance to $3.06 billion to $3.07 billion, up from $3.04 billion to $3.06 billion.It also hiked its full-year adjusted earnings per share (EPS) outlook to $7.06 to $7.11, up from $6.65 to $6.85, citing strong demand for its high-value product (HVP) components used in GLP-1 drugs for weight loss and diabetes regulation. In Q3, HVP components accounted for 48% of the company's total net sales.The firm, however, flagged that it continues to anticipate $15 million to $20 million in tariff-related costs this year.<h2 class="st-heading-2">CEO Remarks</h2>Chief Executive Eric M. Green stated that several factors drove HVP component sales in Q3. “First, elastomers for GLP-1s had strong growth and now account for 9% of total company sales. We benefit from our longstanding relationships as we partner with our customers in this market, supporting them as they expand their GLP-1 franchises…We expect this market to continue to evolve as there are a number of new early-stage trials seeking to expand the range of indications and treatments using GLP-1s,” Green said.He added that the company, which includes weight-loss drugmakers Eli Lilly and Novo Nordisk among its customers, is also collaborating with customers who are launching new GLP-1 molecules and generics.<h2 class="st-heading-2">Third Quarter Earnings</h2>For the third quarter (Q3), West Pharmaceutical reported adjusted and diluted EPS of $1.96, compared to $1.85 in the same period last year, and above an analyst estimate of $1.68, according to data from Fiscal AI. Net sales increased 7.7% year-over-year to $804.6 million in the quarter.The company reported a 16.3% increase in net sales of its HVP components to $390 million in the quarter. Contract-manufactured products segment net sales, meanwhile, rose 8% to $157.1 million, driven by increased sales of self-injection devices for obesity and diabetes.Evercore ISI analyst Daniel Markowitz raised the firm's price target on West Pharmaceutical to $390 from $350 while keeping an ‘Outperform’ rating on the shares following the earnings call.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/WST">WST stock</a> improved from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:619/59;" src="data:image/png;base64,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" width="619" height="59" alt="WST's Sentiment Meter and Message Volume as of 2:15 p.m. ET on Oct. 23, 2025 | Source: Stocktwits"><figcaption>WST's Sentiment Meter and Message Volume as of 2:15 p.m. ET on Oct. 23, 2025 | Source: Stocktwits</figcaption></figure>WST stock is down by 5% this year but has risen over 8% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/staar-surgical-stock-rises-after-adjournment-of-stockholders-meeting-to-discuss-proposed-merger-with-alcon/cLG4FXDR3rj">STAAR Surgical Stock Rises After Adjournment Of Stockholders’ Meeting To Discuss Proposed Merger With Alcon</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration a West Pharmaceutical Services logo is seen on a mobile phone screen in front of a graph. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

WST Stock Soars After Company Raises Full-Year Guidance On Strong Demand For GLP-1 Drug Components

The Pennsylvania-headquartered company raised its full-year net sales guidance to $3.06 billion to $3.07 billion, up from $3.04 billion to $3.06 billion. 

Shares of Humana (HUM) rose 3% on Thursday afternoon after the company affirmed its full-year earnings per share guidance provided in July.The insurer stated that it expects adjusted earnings per common share of $17 for the year ending Dec. 31, 2025, and diluted earnings per share of $13.77.The firm also stated that its preliminary 2026 Medicare Advantage (MA) Star Ratings align with the assumptions in its financial planning. As a result, there is no change to the incremental earnings potential for 2025 to 2028. The ratings data provided by the Centers for Medicare and Medicaid Services was inadvertently accessible on CMS Plan Finder for a brief period on Oct. 1, 2025, the company stated.CMS assigns a star rating to Medicare Advantage plans, ranging from one to five, with five being the highest rating. Beneficiaries can use this data to help choose plans, and insurance companies can receive government bonus payments for higher ratings.Humana has about 20% of its members currently enrolled in Medicare plans rated four stars and above for 2026, and 14% of members in 4.5-star plans for 2026, it said.“Based on all information available to date, the company remains confident in its 2026 Individual MA pricing and benefit design, including the expectation that it will double individual MA pre-tax margin in 2026 (excluding Stars), and believes it is positioned to return to membership growth in 2026,” the firm <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sec.gov/Archives/edgar/data/49071/000004907125000048/hum-20251002.htm">said</a>.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/HUM">HUM stock</a> rose from ‘neutral’ to ‘bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:625/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_02_at_1_48_22_PM_png_d2e549fd89.webp" alt="HUM's Sentiment Meter and Message Volume as of 2 p.m. ET on Oct. 02, 2025 | Source: Stocktwits" width="625" height="62"><figcaption>HUM's Sentiment Meter and Message Volume as of 2 p.m. ET on Oct. 02, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user reported selling their holdings in Humana, citing excessive volatility.<stembedurl>https://stocktwits.com/Felo3179/message/630807403</stembedurl>HUM stock has risen 3% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/immuron-stock-rallies-after-ceo-dismisses-us-pharma-tariff-impact/chCrSSWR3f5">Immuron Stock Rallies After CEO Dismisses US Pharma Tariff Impact, Provides Positive Pipeline Updates</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The MyHumana app page is displayed on a smartphone in the Apple App Store in front of the Humana Inc logo on October 30, 2024 in Chongqing, China. (Photo by Cheng Xin/Getty Images)

Humana Stock Rises After Insurer Reaffirms Full-Year Earnings Guidance

The firm also stated that its preliminary 2026 Medicare Advantage Star Ratings align with the assumptions in its financial planning, and as a result, there is no change to the incremental earnings potential for 2025 to 2028.

Global X Funds - Global X S&P 500 Risk Managed Income ETF

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

XRMI
Global X S&P 500 Risk Managed Income

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest XRMI News

XRMIGlobal X S&P 500 Risk Managed Income